(S)-1-Boc-2,3-Dihydro-2-Pyrrolecarboxylic Acid Ethyl Ester

For pilot- and production-scale preparation of (S)-Boc-proline ethyl ester, the unsaturated precursor is hydrogenated in a 500–2000 L glass-lined autoclave (Pfaudler type) charged with 5% Pd/C (10% w/w dry basis) and absolute ethanol. The reactor is inerted with nitrogen three times, then pressurized to 3.0–3.5 bar hydrogen and stirred at 500 rpm at 25 ± 2 °C. In-process control tracks hydrogen uptake via a Brooks mass flow controller set to stop when 1.05–1.10 equiv H₂ is consumed, and confirmation of double-bond saturation is obtained by the disappearance of the vinyl proton signal at δ 5.8–6.2 ppm in ¹H NMR (CDCl₃, 300 MHz). The slurry is filtered through a 0.2 µm PTFE membrane cartridge, treated with activated charcoal (Norit SX Plus, 5% w/w) to adsorb colloidal palladium, and concentrated under reduced pressure (<100 mbar, 40°C). Enantiomeric purity is verified by chiral HPLC on Chiralpak IA (hexane/EtOH 90:10, 0.7 mL/min, 220 nm), targeting ≥ 99.5% ee. Residual palladium is quantified by ICP-OES per USP <233>, with an acceptance limit of <5 ppm to comply with ICH Q3D oral concentration limits. The optical rotation recorded at 20°C (c=1, MeOH, Ph. Eur. method 2.2.7) lies in the range [α]_D²⁰ = –52° to –54°. Process development has identified that temperature excursions above 35°C during hydrogenation promote α-carbon racemization, elevating the D-enantiomer content above the 0.5% threshold permitted by the drug master file of a registered intermediate. Consequently, vessel jacket temperature control must employ a E&K cascade PID loop with Pt100 probes inserted directly into the liquid phase, not the jacket outlet, to prevent overshoot. Catalyst poisons such as organic sulfides must be rigorously excluded; incoming solvents are pre-tested for sulfur by GC-PFPD (Agilent 7890B with 0.5 ppm detection limit). The hydrogenated product is stored under argon at 2–8°C in HDPE drums lined with double LDPE bags, with a retest interval of 12 months when moisture content (Karl Fischer titration, Metrohm) remains below 0.1%. A representative batch analysis is compiled in Table 1.

What Drives Selection of this Dihydropyrrole Ester as a Peptide Bond Isostere Precursor?

The electron-deficient double bond in the pyrroline ring enables stereoselective conjugate addition by protected thiols, amines, and carbon nucleophiles to generate constrained proline analogues that serve as peptide bond isosteres. In a typical procedure, 1.2 eq of N-Boc-L-cysteine ethyl ester is dissolved in anhydrous DMF and treated with DIPEA (2.5 eq) at 0–5°C under nitrogen. The dihydropyrrole ester is added in one portion, and the mixture is aged for 18–24 h while warming slowly to 20°C. Michael addition proceeds with >95% diastereomeric excess (Cys R-configuration at sulfur-linked carbon) as determined by HPLC on a YMC-Pack Pro C18 column (4.6×150 mm, 3 µm) using a gradient of 30% to 70% acetonitrile in 0.1% TFA over 30 min, detection at 214 nm. After aqueous workup and ester hydrolysis with LiOH (1.5 eq) in THF/H₂O (2:1) at 0°C, the crude acid is purified over silica gel 230–400 mesh with gradient elution (CH₂Cl₂ to CH₂Cl₂/MeOH 95:5). The resulting constrained thiaproline analogue is Fmoc-protected at the amine site not masked by Boc and loaded onto 2-chlorotrityl chloride resin (1.2 mmol/g) under anhydrous conditions for solid-phase peptide synthesis using HATU/DIEA in DMF. The rigidified macrocyclic peptides that emerge from this building block are found in the core structures of several HCV NS3/4A protease inhibitors, where the sulfur-linked proline mimic contributes to a pre-organized β-hairpin geometry. Absolute configuration of the Michael adduct was assigned by single-crystal X-ray diffraction using a Bruker D8 Venture diffractometer with Cu Kα radiation. The crystal data are deposited at the CCDC under a peer-reviewed entry. All steps are executed in a GMP facility with room classification ISO 7, and the final protected peptidomimetics are tested for residual DMF (<880 ppm) by GC-HS per ICH Q3C.

Cycloaddition-Derived Spirocycles for Fragment-Based Drug Discovery

When the dihydropyrrole ester functions as a chiral dienophile in Diels-Alder cycloadditions, a single operational step generates spirocyclic pyrrolidine-lactam cores that are screened as fragments. The reaction with cyclopentadiene (3.0 eq) in anhydrous CH₂Cl₂ at –78°C in the presence of 1.0 eq of ZnCl₂ (freshly fused) gives the endo cycloadduct with an endo/exo ratio of >20:1 confirmed by ¹H NOESY coupling between the bridgehead proton and the ester methylene. The reaction is monitored by TLC (silica, hexane/EtOAc 7:3) and quenched with saturated NH₄Cl after 4 h. After standard workup and filtration through Celite, the crude product is purified by flash chromatography on a Biotage Isolera system with a SNAP Ultra 100 g cartridge. The pure spiro ester is deprotected with TFA/CH₂Cl₂ (1:1) containing 2.5% triisopropylsilane as scavenger for 2 h at 20°C, neutralized over Amberlite IRA-400 (OH⁻ form), and lyophilized (Virtis Genesis SQ, shelf –40°C, <0.1 mbar) to yield the free amine trifluoroacetate salt. This rigid, three-dimensional scaffold is submitted to protein kinase fragment screens with a solubility threshold of >1 mM in aqueous buffer (PBS, pH 7.4, measured by dynamic light scattering on a Malvern Zetasizer Nano). The isolated yield of the endo cycloadduct after chromatography averages 78%. Published data for this specific spirocyclic fragment configuration in a publicly disclosed drug candidate is limited; however, the scaffold consistently passes PAINS liability filters (AlphaScreen interference) at concentrations below 10 µM.

Saponification of the ethyl ester to the free acid uses 2N NaOH (1.3 eq) in a mixture of THF:MeOH:H₂O (3:2:1) at 0°C to 20°C over 4 h. When pH is adjusted to 3.0–3.5 with 5% citric acid and extracted with ethyl acetate, the resulting (S)-1-Boc-2,3-dihydro-2-pyrrolecarboxylic acid is obtained as a white solid after drying under vacuum (<1 mbar, 35°C). This acid requires storage under argon at –20°C to prevent decarboxylation, a side reaction that becomes noticeable above 25°C as monitored by the 1710 cm⁻¹ carbonyl stretching band shift in FTIR. The acid is coupled to amine-functionalized poly(ethylene glycol) linkers (PEG_n-NH₂, n=4, 8, 12) via the mixed carbonic anhydride method. Isobutyl chloroformate (1.1 eq) is added to the acid in dry THF containing N-methylmorpholine (1.2 eq) at –15°C. After 30 min, the PEG-amine (1.0 eq) is introduced, and the reaction is stirred for 12 h at 4°C. The dihydropyrrole-terminated PEG is purified by preparative HPLC on a 10 µm, 250×21.2 mm C18 column with a linear gradient of water/acetonitrile (0.1% TFA) at 20 mL/min. Fractions are lyophilized on a Labconco FreeZone 2.5 L freeze dryer. These PEGylated building blocks are integrated into drug-linker constructs for antibody-drug conjugates, with the Boc group removed by 4N HCl/dioxane just before conjugation to a maleimide handle. The residual solvent profile is verified by GC-HS according to USP <467>, and the conjugate monomer ratio is confirmed by SEC-MALS using a Wyatt Dawn HELEOS-II detector. The mass balance purity by Q-TOF exceeds 95% (ESI positive mode, Agilent 6530).

Accessing Fluorinated Proline Analogues Through Electrophilic Fluorination of the Enamine Double Bond

Electrophilic fluorination of the dihydropyrrole ester with Selectfluor (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate), 1.1 eq) in dry acetonitrile at 0°C yields a mixture of syn and anti fluorinated adducts. Triethylamine (0.5 eq) is added as a buffer to neutralize liberated HBF₄ and minimize acid-catalyzed epimerization at the C-2 carbon. After 8 h, the solvent is removed under reduced pressure, and the residue is partitioned between EtOAc and saturated NaHCO₃. The organic layer is dried over Na₂SO₄, filtered, and concentrated. The diastereomers are separated by flash chromatography on silica gel 230–400 mesh with hexane/ethyl acetate 8:2. The isolated major diastereomer undergoes subsequent hydrogenation over 5% Rh/Al₂O₃ (5% w/w) in ethanol at 3 bar and 20°C to saturate the ring while retaining the fluorine atom, providing a 4-fluoro-L-proline ethyl ester derivative. The fluorine stereochemistry at C-4 is confirmed by ¹⁹F NMR (Bruker 400 MHz, CDCl₃) with a characteristic multiplet at δ –165 to –175 ppm. The ee of the product remains >98% when the fluorination is conducted below 5°C and the silica column is pre-equilibrated with mobile phase cooled to 4°C. This fluorinated proline ester is a key intermediate for PET tracer precursors that require radiolabeling with ¹⁸F at the no-carrier-added level; purity is tested by radio-HPLC on a Phenomenex Luna C18 column (5 µm, 4.6×150 mm) with ammonium formate buffer (pH 4.5) and ethanol as organic modifier.

Blending the (S)-1-Boc-2,3-dihydro-2-pyrrolecarboxylic acid ethyl ester into anhydrous acetonitrile or DMF for standard peptide coupling requires moisture content in the solvent below 50 ppm (Karl Fischer) and storage over activated 3 Å molecular sieves under a nitrogen blanket.